Objective: The Carpentier-Edwards (CE) Physio II ring is a new prosthetic ring designed to accommodate the changing pathology seen in the spectrum of degenerative valve disease, particularly the larger anterior leaflet in repair of the Barlow valve. The aim of our study was to assess the safety and efficacy of mitral valve (MV) repair with the CE Physio II ring. Methods: Between April 2009 and March 2010, 100 patients underwent MV repair using the Physio II ring. Median age of patients was 70 years (54-85 years). The left ventricle (LV) was moderately (30-50%; n = 21) or severely (<30%; n = 6) impaired in 27 patients preoperatively. Mitral regurgitation (MR) was due to degenerative disease in 87 patients (bileaflet prolapse: 34 patients). Mean logistic EuroSCORE was 10.07 AE 8.9 and mean follow-up was 6.3 AE 2.4 months. Results: Seventeen patients were non-elective (eight emergencies), five were re-do operations and 23 Maze AE pulmonary vein isolations, and 14 tricuspid annuloplasties were performed. Neo-chordae were inserted in 50 patients (50%), whereas sliding annuloplasty was performed only in three patients. The median ring size was 32 mm (range 26-40 mm). On-table trans-oesophageal echocardiography (TOE) showed trivial/no MR in 87 patients, and mild in 13 patients, and there were no cases of systolic anterior motion (SAM). There were two re-explorations for bleeding and two patients required haemofiltration. There were no strokes or deep sternal wound infections (DSWIs). There was one hospital death (1%). At discharge, mean left ventricular end-diastolic (LVEDD) was 4.8 AE 0.7 cm compared with 5.5 AE 0.8 cm preoperatively ( p = 0.03) and mean left ventricular endsystolic (LVESD) was 3.3 AE 0.5 cm as compared with 3.6 AE 0.8 preoperatively ( p = 0.4). There was no MR in 87 patients and mild MR in 13 patients. The mean mitral valve area (MVA) was 2.8 AE 0.7 cm 2 . The mean systolic pulmonary artery pressure (SPAP) was 26.6 AE 7.3 mmHg as compared with 50.9 AE 17.2 mmHg preoperatively ( p = 0.02). During follow-up, there were no thrombo-embolic complications, re-operation, endocarditis or deaths. Conclusions: MV repair with the Physio II ring has excellent short-term results, including subgroups with large anterior mitral valve leaflet (AMVL). Moreover, the dimensional ratios of the ring may allow it to be used for MV repair for degenerative MV disease, irrespective of anterior leaflet size. Crown
Introduction
Mitral valve (MV) repair is considered the treatment of choice for mitral regurgitation (MR), and is preferred to prosthetic valve replacement, whenever technically possible. MV repair preserves native valve function and offers good durability and long-term outcomes without the need for anticoagulation. Since Carpentier's first description of his approach for MV repair in 1968 [1] , the techniques have evolved and although there are many variations, the principle of ensuring good co-aptation along the whole of the closure line without systolic anterior motion (SAM) is common to all. Modern MV reconstruction is not only associated with low operative morbidity and mortality [2] , but has also been shown to improve left ventricular (LV) function [3] and increase long-term survival in MR, secondary to a range of pathologies [4] . Annular deformity is the typical finding in MR, and annuloplasty with a prosthetic ring corrects annular dilatation and allows remodelling to take place. Several studies have confirmed the long-term efficacy of annuloplasty ring repair [5] [6] [7] . The range of annuloplasty rings available is now quite extensive and reflects the lack of consensus on the features of a durable and effective device. For degenerative disease, a balance needs to be struck between rigidity of design which can aid in the remodelling process, and flexibility of the ring which preserves the dynamic function of the mitral annulus [8] . In addition, the incidence of detrimental SAM of the anterior mitral leaflet, adverse diastolic gradients across the repair and the impact on LV function must all be borne in mind when choosing between annuloplasty devices [9] .
Outcomes for the Carpentier-Edwards (CE) Physio annuloplasty ring (Edwards Lifesciences, Irvine, CA, USA) were first published in the mid-1990s, since when it has consistently demonstrated good short-and medium-term efficacy [10] . The CE Physio II (Edwards Lifesciences, Irvine, CA, USA) represents the next generation of mitral annuloplasty rings, and has entered surgical practice recently. The Physio II is designed to accommodate the changing pathology seen in the spectrum of degenerative valve disease, particularly the larger anterior leaflet in repair of the Barlow valve, to prevent SAM and to facilitate the use of a complete ring in the majority of cases. In addition, its design incorporates a 'double-saddle' to maximise the distribution of stress across the reconstructed MV [11] . The ring also retains the selective features of rigidity anteriorly and flexibility posteriorly found in the original Physio ring. To date, no studies have reported the early outcomes of use of the CE Physio II annuloplasty ring, and the aim of this study is to assess its safety and efficacy in MV repair in a heterogeneous sample of patients with MR.
Methods

Patient population and indications
This retrospective study identified patients from bespoke database and involved case-note and electronic record review. One hundred patients (male; n = 62) underwent MV repair using the CE Physio II ring between April 2009 and March 2010, and were included in this study. The median age of the patients was 70 years (range 54-85 years). Common presenting complaints included dyspnoea (n = 79), angina (n = 11), tiredness (n = 17) and palpitations (n = 2). Preoperatively, 38 patients were in the New York Heart Association (NYHA) class III or IV. The patients had a significant number of co-morbidities (Table 1) with 49 patients having a history of permanent or paroxysmal atrial fibrillation (AF) or other atrial arrhythmia. Of these, 43 were on long-term antiarrhythmic drugs, 38 were on warfarin and three were fitted with permanent pacemakers.
The underlying pathology was degenerative disease in the majority of cases (n = 87), although in 13 patients the primary cause of MR was ischaemic cardiomyopathy. Severe MR, even if asymptomatic, was an indication for surgery. In patients with other indications for open-heart surgery, moderate MR was an indication for MV repair. Echocardiography defined the aetiology of MR with 13 secondary to annular dilatation and leaflet tethering (Carpentier I and IIIb) , 34 bileaflet prolapse and 41 due to posterior leaflet prolapse. Most interventions were elective (n = 83), although urgent (n = 9) and emergency (n = 8) procedures were also performed. The mean preoperative EuroSCORE was 6.6 AE 2.5 and two patients required preoperative inotropes.
Echocardiography
Quantitative parameters such as effective regurgitant orifice area (EROA; !0.40 cm 2 ), regurgitant fraction (!50%), regurgitant volume (!60 ml beat À1 ), vena contract width (!0.7 cm) and Doppler parameters such as colour flow jet area (severe: large central jet (usually >10 cm 2 or >40% of LA area) or variable size wall impinging jet swirling in LA) were used to assess the severity of MR. The EROA was determined by dividing the regurgitant flow rate (2pr 2 Â aliasing velocity; r = proximal isovelocity surface area radius) by peak MR velocity. Systolic pulmonary artery pressures (SPAPs) were estimated by continuous-wave Doppler with the simplified Bernoulli equation (4 Â (peak velocity of tricuspid regurgitation) 2 ) with 5 mmHg added for the estimated right atrial pressure. Left ventricular end-diastolic (LVEDD) and end-systolic (LVESD) diameters were measured from parasternal M-mode views, and ejection fraction (EF) of the LV was calculated by the biplane Simpson method. Preoperative echocardiography demonstrated that LV function was moderately (EF 30-50%; n = 21) or severely (EF < 30%; n = 6) impaired in 27 patients with mean LVEDD and LVESD of 5.5 AE 0.8 cm and 3.6 AE 0.8 cm, respectively. The mean SPAP in our cohort was 50.9 AE 17.2 mmHg prior to surgery (Table 1) . 
Operative technique
Intra-operative trans-oesophageal echocardiography was performed in all cases. Surgery was undertaken through a median sternotomy and cardiopulmonary bypass (CPB) was established via either aorto-bicaval or aorto-atrial cannulation. Cardiac arrest and cardio-protection were achieved through moderate hypothermia and cold-blood cardioplegia. The MV was exposed through a longitudinal incision after developing the interatrial groove. Operative techniques were largely based upon those devised by Carpentier and Perier, and included resection of the prolapsing valve segment, leaflet reconstruction, sliding plasty and remodelling with the annuloplasty ring [6] . Where appropriate, neo-chordae were used. A horizontal mattress suture with pledget-supported CV-4 polytetrafluoroethylene (PTFE; Gore-Tex suture; W.L. Gore & Associates, Inc, Flagstaff, AZ, USA) was initially placed through the fibrous thickened part of the appropriate papillary muscle. Both ends of the suture were then passed through the prolapsing scallop 3-5 mm from the free edge of the leaflet from the ventricular side to the atrial side. The greater distance from the free edge was used when there was an excessive amount of tissue, as this produces a rolling effect that reduces the leaflet length and the risk of SAM of the MV. One of the suture ends was then passed through the leaflet edge again from the ventricular side to the atrial side to produce a single loop [12] . Additional PTFE sutures were implanted as appropriate to the number of prolapsing scallops. After sizing of the anterior leaflet, an annuloplasty ring (Physio II, Edwards Lifesciences, Irvine, CA, USA) was implanted with interrupted 2/0 Ethibond sutures (Ethicon, Inc, Somerville, NJ, USA). Valve competency was subsequently tested by injecting cold saline into the LV across the valve. With the LV full, the neo-chordae were adjusted to ensure good leaflet coaptation. Before the left atrium was closed, the MV leaflets were observed to be bulging with appropriate areas of coaptation and no residual regurgitation or prolapse. Neochordae were inserted in 50 patients, whereas sliding plasty was performed in only three patients. The median ring size was 32 mm (range 26-40 mm). Concomitant procedures (Table 2) were performed in 56 patients, with 27 antiarrhythmic procedures (Maze, pulmonary vein isolation (PVI), left atrial appendage (LAA) excision), 14 tricuspid annuloplasties and 15 coronary artery bypass grafts (CABG). There were five re-do procedures. Six patients required the insertion of intra-aortic balloon pumps (IABPs) intra-operatively to aid in weaning from CPB. Mean CPB time and aortic cross-clamp time were 114.3 AE 29 min and 86.5 AE 83 min, respectively.
Anticoagulation
All patients received aspirin 75 mg, unless contraindications existed. Additional warfarin was administered for a period of 6 months only to those patients, who underwent concomitant Maze AE PVI. At 6 months, warfarin was continued only if they remained in AF.
Statistical analyses
Statistical analysis was performed using Statistical Package for the Social Sciences Program, SPSS Version 16.0 (SPSS, Inc, Chicago, IL, USA) and Microsoft Excel. Data were expressed as frequency with percentage, mean with standard deviation (SD) or as median with range, as appropriate. Continuous variables were compared using the two-tailed Student's t-test. A p-value <0.05 was considered statistically significant.
Results
The 100 patients in this study were followed up for a mean of 6.3 AE 2.4 months. At each follow-up, both clinical assessment and transthoracic echocardiography were performed. During this time, there was one death which was due to multi-organ dysfunction 4 days after MV repair. The death was not related to any valvular complication. Three patients required re-operation, two for early postoperative bleeding and one at a delayed date for sternal re-wiring following fracture of the wires and sternal instability. There were also a number of other complications (Table 3) , including multiorgan dysfunction (n = 3), prolonged ventilatory wean requiring tracheostomy (n = 5), permanent pacemaker insertion (n = 1), pleural effusions or pneumothoraces requiring chest drain re-insertion (n = 6), renal insufficiency necessitating haemofiltration (n = 2) and two cases of gastric Postoperative transthoracic echocardiography was undertaken in all patients prior to discharge and at each follow-up. No or trivial MR was present in 87 patients, with mild MR in the remaining 13. The postoperative MV area was 2.8 AE 0.7 cm 2 with a mean MV gradient of 3.5 AE 1.2 mmHg. mmHg. Importantly, no cases of SAM were identified on echocardiography. The mean SPAP also decreased significantly following surgery, from 50.9 AE 17.2 mmHg to 26.6 AE 7.3 mmHg ( p = 0.02). Furthermore, the mean LVEDD showed a significant reduction from 5.5 AE 0.8 cm to 4.8 AE 0.7 cm ( p = 0.03), although there was no difference in LVESD (preoperative 3.6 AE 0.8 cm, postoperative 3.3 AE 0.5 cm, p = 0.4). A total of 58 patients had normal LV function at discharge from hospital, whilst a further 16 and 23 had mild and moderately impaired LV function, respectively.
Discussion
The pioneering work on MV repair was accomplished in the 1970s through the achievements of Carpentier [1] . Indeed, efficacious long-term outcomes from MV repair are best achieved by surgeons experienced in the intricacies of MV repair [13] . Furthermore, decisions regarding the choice of intervention are often complex and can sometimes only be made intra-operatively and with the benefit of experience. This makes any standardisation of practice inherently problematic. Despite this, mitral annuloplasty has become one of the key features of MV repair with proven short-and long-term efficacy [6, 7] . The theory underpinning what constitutes a 'gold standard' annuloplasty ring is hotly debated [14] . An entirely rigid ring offers robust annular remodelling potential yet runs the risk of inducing SAM and left-ventricular outflow tract obstruction [15] . This may, in turn, impact negatively on LV function or result in subvalvular stenosis [2, 16] , although there is debate over whether this is clinically significant [17] . A completely flexible ring, by contrast, allows dynamic movement of the annulus, but offers little structural integrity to facilitate remodelling and may predispose to residual MR. Annuloplasty rings, such as the Physio and Physio II, with selective flexibility and rigidity in different planes and locations on the ring, have consequently been developed. These aim to optimise remodelling whilst allowing some degree of movement at the annulus. These rings also incorporate 'saddles' to better fit the structures surrounding the mitral annulus, including the aortic root.
This study reports the early outcomes and experience of use of the CE Physio II annuloplasty ring in MV repair in a heterogeneous sample of patients with MR due to multiple underlying pathologies. At the time of writing, this is the sole study to investigate the short-term safety and efficacy of the CE Physio II ring. The new ring incorporates many of the design features that have made the original CE Physio popular; however, the CE Physio II is a novel design, which must be assessed in an independent clinical setting prior to its validation as a safe device to use in MV repair. As mentioned above, in larger sizes, the CE Physio II ring is more circular than the Physio so as to accommodate the larger anterior leaflet of the Barlow valve and to prevent SAM. In addition, the 'double saddle' aims to redistribute the stress moreeffectively across the MV following repair. In the year prior to introduction of the Physio II ring, we implanted either the Physio ring or the Cosgrove-Edwards ring. Our choice was largely determined by the degree of accessory mitral valve leaflet (AMVL) pathology. Although our primary philosophy favoured the use of a complete, semi-flexible ring to aid the stability and longevity of repair, we found that, in some patients, the Physio ring would not accommodate the enlarged AMVL, seen particularly in Barlow valves. Hence, in patients where there was excess tissue in AMVL and hence longer AMVL height, we favoured the Cosgrove-Edwards ring, which because it is an incomplete ring, does not constrain the AMVL and hence avoided the potential for SAM.
In our series, we report low operative morbidity and mortality, as well as a consistent reduction in MR amongst our sample. There were also significant reductions in both SPAP and LVEDD, indicative of improved haemodynamics, although we were unable to demonstrate an improvement in LVEF. This is not unexpected in surgery for mitral regurgitation, given the pathological offloading through the regurgitant valve, preoperatively. We also observed an acceptable gradient across the MV repair, and there were no cases of SAM, which [18] . Another prospective randomised study by Shahin et al. looked at the relative performance of the rigid CE Classic and the Physio rings, and again failed to show any difference in morbidity, valve function and LV function at a mean follow-up of 5.1 years [19] . Other retrospective studies have also not demonstrated any significant difference in outcome between different annuloplasty ring types [20, 21] . This is in stark contrast to several complex echocardiographic studies, which have consistently shown better LV function after flexible ring annuloplasty [2, [22] [23] [24] . It is thus possible that the echocardiographic findings of improved LV function for flexible rings do not correlate with clinical outcome. This is a retrospective study, which has investigated the early outcomes of a single annuloplasty ring at one centre. As such, no direct comparisons can be made with other rings, and this study is not ideal to inform clinical decision making regarding annuloplasty device choice. However, the Physio II ring does provide an effective remodelling annuloplasty across the range of degenerative MV pathologies, and there was no need to use a partial ring during the period of this study. Although the follow-up is short, this is the first study to report operative data using the new CE Physio II ring. All studies highlighting novel advances in surgical technique and technology are vital to raising awareness amongst clinicians and to expand the use and evidence base of new interventions.
The CE Physio II annuloplasty ring provides a safe and efficacious means of MV remodelling without inducing major early complications including SAM and left-ventricular outflow tract obstruction. If your philosophy is to favour a complete ring, which reshapes the MV annulus, believing that this provides a long-lasting mitral repair, then our initial experience with the Physio II ring is encouraging. However, its performance in the medium-and long term remains to be evaluated.
